1-4 of 4
Mark Morrow
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors

Free
Jennifer R. Diamond, Bruno R. Bastos, Ryan J. Hansen, Daniel L. Gustafson, S. Gail Eckhardt, Eunice L. Kwak, Shuchi S. Pandya, Graham C. Fletcher, Todd M. Pitts, Gillian N. Kulikowski, Mark Morrow, Jamie Arnott, Mark R. Bray, Carolyn Sidor, Wells Messersmith, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 849–860.
https://doi.org/10.1158/1078-0432.CCR-10-2144
Published: 15 February 2011
View article titled, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors
Open the PDF for Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Investigation of Two Dosing Schedules of Vandetanib (ZD6474), an Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, in Combination with Irinotecan in a Human Colon Cancer Xenograft Model

Free
Teresa Troiani, Natalie J. Serkova, Daniel L. Gustafson, Thomas K. Henthorn, Owen Lockerbie, Andrea Merz, Michael Long, Mark Morrow, Fortunato Ciardiello, S. Gail Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (21): 6450–6458.
https://doi.org/10.1158/1078-0432.CCR-07-1094
Published: 01 November 2007
View article titled, Investigation of Two Dosing Schedules of Vandetanib (ZD6474), an Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, in Combination with Irinotecan in a Human Colon Cancer Xenograft Model
Open the PDF for Investigation of Two Dosing Schedules of Vandetanib (ZD6474), an Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, in Combination with Irinotecan in a Human Colon Cancer Xenograft Model in another window
Journal Articles

A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors

Free
Michele Basche, Daniel L. Gustafson, Scott N. Holden, Cindy L. O'Bryant, Lia Gore, Samir Witta, Mary Kay Schultz, Mark Morrow, Adrah Levin, Brian R. Creese, Michael Kangas, Kaye Roberts, Thu Nguyen, Kat Davis, Russell S. Addison, Jane C. Moore, S. Gail Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (18): 5471–5480.
https://doi.org/10.1158/1078-0432.CCR-05-2423
Published: 25 September 2006
View article titled, A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients

Free
Bhuvaneswari Ramaswamy, Anthony D. Elias, Nicole T. Kelbick, Angela Dodley, Mark Morrow, Marsha Hauger, Joan Allen, Chris Rhoades, Kari Kendra, Helen X. Chen, S. Gail Eckhardt, Charles L. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (10): 3124–3129.
https://doi.org/10.1158/1078-0432.CCR-05-2603
Published: 17 May 2006
View article titled, Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients
Open the PDF for Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients in another window